Literature DB >> 15198527

Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP Apparatus 2 and 3.

Janice Cacace1, Eugene E Reilly, Anton Amann.   

Abstract

The purpose of this study was to evaluate the effect of pH on the dissolution behavior of metaxalone in the marketed product Skelaxin tablets. The dissolution was evaluated using United States Pharmacopeia (USP) dissolution Apparatus 2 and 3 at pHs ranging from 1.5 to 7.4. Results from these studies show that the dissolution of this product is pH dependent. At low pH (simulated gastric fluid, pH 1.5), the dissolution of metaxalone from Skelaxin tablets was less than 10% over 75 minutes; whereas, dissolution at pH 4.5 showed greater than 90% release in the same time period. These results were consistent for both Apparatus 2 and 3. This suggests that Skelaxin Tablets should be considered a delayed release dosage form.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198527      PMCID: PMC2784857          DOI: 10.1208/pt050106

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  4 in total

1.  A review of three commonly prescribed skeletal muscle relaxants.

Authors:  R N Harden; C Argoff
Journal:  J Back Musculoskelet Rehabil       Date:  2000-01-01       Impact factor: 1.398

2.  Metabolism of metaxalone.

Authors:  R B Bruce; L Turnbull; J Newman; J Pitts
Journal:  J Med Chem       Date:  1966-05       Impact factor: 7.446

Review 3.  Providing relief from headache pain. Current options for acute and prophylactic therapy.

Authors:  T N Ward
Journal:  Postgrad Med       Date:  2000-09-01       Impact factor: 3.840

4.  A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy.

Authors:  M A Pfeifer; D R Ross; J P Schrage; D A Gelber; M P Schumer; G M Crain; S J Markwell; S Jung
Journal:  Diabetes Care       Date:  1993-08       Impact factor: 19.112

  4 in total
  5 in total

1.  Calcium-alginate microparticles for sustained release of catechin prepared via an emulsion gelation technique.

Authors:  Eun Suh Kim; Ji-Soo Lee; Hyeon Gyu Lee
Journal:  Food Sci Biotechnol       Date:  2016-10-31       Impact factor: 2.391

2.  Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.

Authors:  Lucija Vuletić; M Zahirul I Khan; Drago Špoljarić; Maja Radić; Biserka Cetina-Čižmek; Jelena Filipović-Grčić
Journal:  Pharm Res       Date:  2018-06-22       Impact factor: 4.200

3.  Development of a Stability-Indicating RP-UPLC Method for Rapid Determination of Metaxalone and its Degradation Products in Solid Oral Dosage Form.

Authors:  Rakshit Kanubhai Trivedi; Mukesh C Patel
Journal:  Sci Pharm       Date:  2012-02-21

4.  New Stability-Indicating RP-HPLC Method for Determination of Diclofenac Potassium and Metaxalone from their Combined Dosage Form.

Authors:  Sagar Suman Panda; Debasis Patanaik; Bera V V Ravi Kumar
Journal:  Sci Pharm       Date:  2011-12-05

5.  Kinetics study of metaxalone degradation under hydrolytic, oxidative and thermal stress conditions using stability-indicating HPLC method.

Authors:  Vamsi Krishna Marothu; Rajendra N Dash; Saritha Vemula; Shravani Donkena; Ramesh Devi; Madhavi Gorrepati
Journal:  J Pharm Anal       Date:  2012-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.